Poster
192
(#192) Real-world Outcomes of Facilitated Psilocybin Sessions under Oregon's Legal Framework.
Psych Congress 2025
Abstract: Clinical trials have shown promising results for psilocybin in treating psychiatric conditions such as treatment-resistant depression and PTSD, with multiple biopharmaceutical companies advancing towards FDA approval. In 2020, Oregon's Measure 109 established the first legal framework for supervised psilocybin services, with licensed centers beginning services in 2023. However, real-world clinical outcomes data from these services remain unknown. This study evaluates changes in self-reported symptoms of depression, anxiety, and well-being before and after facilitated psilocybin sessions under Oregon's legal framework, presenting preliminary findings from a naturalistic observational study.
Eighty-eight adults completed validated surveys at baseline, ~1 day, and ~30 days post-session. Sessions were conducted by licensed facilitators and followed by integration support. Measures included the PHQ-8, GAD-7, and WHO-5. Linear mixed-effects models assessed changes over time, adjusting for age, sex, dose, medication use, and session type (individual vs. group). The study was approved by WCG IRB.
Significant improvements were observed across all outcomes at 30 days post-session. Adjusted model-predicted depression scores decreased from 11.9 at baseline to 7.3 at 30 days. Anxiety scores decreased from 10.7 at baseline to 5.9. Both depression and anxiety changes reflect a reduction from moderate to mild symptom severity. Well-being scores increased from 3.6 at baseline to 14.3 at 30 days. Preliminary results suggest that facilitated psilocybin sessions administered under a legal framework may significantly enhance mood, reduce anxiety, and improve well-being in real-world settings. Further research is needed to examine underlying mechanisms, response patterns, and long-term outcomes.
Short Description: This study presents real-world data on facilitated psilocybin sessions under Oregon's legal framework. Eighty-eight adults completed surveys measuring depression, anxiety, and well-being at baseline, approximately 1 day after, and approximately 30 days following their psilocybin session. Results showed significant improvements across all measures, with depression and anxiety symptoms decreasing from moderate to mild and well-being substantially increasing. Findings suggest psilocybin sessions are linked to mental health improvements, warranting further research on long-term outcomes and mechanisms.
Name of Sponsoring Organization(s): Bendable Therapy
Osmind
Eighty-eight adults completed validated surveys at baseline, ~1 day, and ~30 days post-session. Sessions were conducted by licensed facilitators and followed by integration support. Measures included the PHQ-8, GAD-7, and WHO-5. Linear mixed-effects models assessed changes over time, adjusting for age, sex, dose, medication use, and session type (individual vs. group). The study was approved by WCG IRB.
Significant improvements were observed across all outcomes at 30 days post-session. Adjusted model-predicted depression scores decreased from 11.9 at baseline to 7.3 at 30 days. Anxiety scores decreased from 10.7 at baseline to 5.9. Both depression and anxiety changes reflect a reduction from moderate to mild symptom severity. Well-being scores increased from 3.6 at baseline to 14.3 at 30 days. Preliminary results suggest that facilitated psilocybin sessions administered under a legal framework may significantly enhance mood, reduce anxiety, and improve well-being in real-world settings. Further research is needed to examine underlying mechanisms, response patterns, and long-term outcomes.
Short Description: This study presents real-world data on facilitated psilocybin sessions under Oregon's legal framework. Eighty-eight adults completed surveys measuring depression, anxiety, and well-being at baseline, approximately 1 day after, and approximately 30 days following their psilocybin session. Results showed significant improvements across all measures, with depression and anxiety symptoms decreasing from moderate to mild and well-being substantially increasing. Findings suggest psilocybin sessions are linked to mental health improvements, warranting further research on long-term outcomes and mechanisms.
Name of Sponsoring Organization(s): Bendable Therapy
Osmind
